Skip to main content
Top
Published in: Arthritis Research & Therapy 4/2006

Open Access 01-08-2006 | Research article

The MHC2TA-168A>G gene polymorphism is not associated with rheumatoid arthritis in Austrian patients

Authors: Babak Yazdani-Biuki, Kerstin Brickmann, Klaus Wohlfahrt, Thomas Mueller, Winfried März, Wilfried Renner, Manuela Gutjahr, Uwe Langsenlehner, Peter Krippl, Thomas C Wascher, Bernhard Paulweber, Winfried Graninger, Hans-Peter Brezinschek

Published in: Arthritis Research & Therapy | Issue 4/2006

Login to get access

Abstract

An association between susceptibility to rheumatoid arthritis (RA) and a common -168A>G polymorphism in the MHC2TA gene with differential major histocompatibility complex (MHC) II molecule expression was recently reported in a Swedish population. The objective of the present study was to replicate this finding by examining the -168A>G polymorphism in an Austrian case–control study. Three hundred and sixty-two unrelated RA cases and 351 sex-matched and age-matched controls as well as 1,709 Austrian healthy individuals were genotyped. All participants were from the same ethnic background. Genotyping was performed using 5' allelic discrimination assays. The association between susceptibility to RA and the -168A>G single nucleotide polymorphism was examined by chi-square test. Comparison was made assuming a dominant effect (AG + GG genotypes versus AA genotype). In contrast to the primary report, the frequency of MHC2TA -168G allele carriers was not significantly different between patients and controls in the Austrian cohort. The homozygous MHC2TA -168 GG genotype was more frequent in matched controls than in Austrian RA patients. There was no association between the presence of RA-specific autoantibodies and the MHC2TA -168 GG genotype. In this cohort of Austrian patients, no association between the MHC2TA polymorphism and RA was found.
Literature
1.
go back to reference Arend WP: The pathophysiology and treatment of rheumatoid arthritis. Arthritis Rheum. 1997, 40: 595-597.CrossRefPubMed Arend WP: The pathophysiology and treatment of rheumatoid arthritis. Arthritis Rheum. 1997, 40: 595-597.CrossRefPubMed
2.
go back to reference Guillemin F, Saraux A, Guggenbuhl P, Roux CH, Fardellone P, Le Bihan E, Cantagrel A, Chary-Valckenaere I, Euller-Ziegler L, Flipo RM, et al: Prevalence of rheumatoid arthritis in France: 2001. Ann Rheum Dis. 2005, 64: 1427-1430. 10.1136/ard.2004.029199.PubMedCentralCrossRefPubMed Guillemin F, Saraux A, Guggenbuhl P, Roux CH, Fardellone P, Le Bihan E, Cantagrel A, Chary-Valckenaere I, Euller-Ziegler L, Flipo RM, et al: Prevalence of rheumatoid arthritis in France: 2001. Ann Rheum Dis. 2005, 64: 1427-1430. 10.1136/ard.2004.029199.PubMedCentralCrossRefPubMed
3.
go back to reference MacGregor AJ, Bamber S, Silman AJ: A comparison of the performance of different methods of disease classification for rheumatoid arthritis. Results of an analysis from a nationwide twin study. J Rheumatol. 1994, 21: 1420-1426.PubMed MacGregor AJ, Bamber S, Silman AJ: A comparison of the performance of different methods of disease classification for rheumatoid arthritis. Results of an analysis from a nationwide twin study. J Rheumatol. 1994, 21: 1420-1426.PubMed
4.
go back to reference Deighton CM, Walker DJ, Griffiths ID, Roberts DF: The contribution of HLA to rheumatoid arthritis. Clin Genet. 1989, 36: 178-182.CrossRefPubMed Deighton CM, Walker DJ, Griffiths ID, Roberts DF: The contribution of HLA to rheumatoid arthritis. Clin Genet. 1989, 36: 178-182.CrossRefPubMed
5.
go back to reference Wordsworth BP, Lanchbury JS, Sakkas LI, Welsh KI, Panayi GS, Bell JI: HLA-DR4 subtype frequencies in rheumatoid arthritis indicate that DRB1 is the major susceptibility locus within the HLA class II region. Proc Natl Acad Sci USA. 1989, 86: 10049-10053. 10.1073/pnas.86.24.10049.PubMedCentralCrossRefPubMed Wordsworth BP, Lanchbury JS, Sakkas LI, Welsh KI, Panayi GS, Bell JI: HLA-DR4 subtype frequencies in rheumatoid arthritis indicate that DRB1 is the major susceptibility locus within the HLA class II region. Proc Natl Acad Sci USA. 1989, 86: 10049-10053. 10.1073/pnas.86.24.10049.PubMedCentralCrossRefPubMed
6.
go back to reference Weyand CM, Hicok KC, Conn DL, Goronzy JJ: The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann Intern Med. 1992, 117: 801-806.CrossRefPubMed Weyand CM, Hicok KC, Conn DL, Goronzy JJ: The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann Intern Med. 1992, 117: 801-806.CrossRefPubMed
7.
go back to reference MacGregor AJ, Bamber S, Carthy D, Vencovsky J, Mageed RA, Ollier WE, Silman AJ: Heterogeneity of disease phenotype in monozygotic twins concordant for rheumatoid arthritis. Br J Rheumatol. 1995, 34: 215-220.CrossRefPubMed MacGregor AJ, Bamber S, Carthy D, Vencovsky J, Mageed RA, Ollier WE, Silman AJ: Heterogeneity of disease phenotype in monozygotic twins concordant for rheumatoid arthritis. Br J Rheumatol. 1995, 34: 215-220.CrossRefPubMed
8.
go back to reference Plenge RM, Padyukov L, Remmers EF, Purcell S, Lee AT, Karlson EW, Wolfe F, Kastner DL, Alfredsson L, Altshuler D, et al: Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum Genet. 2005, 77: 1044-1060. 10.1086/498651.PubMedCentralCrossRefPubMed Plenge RM, Padyukov L, Remmers EF, Purcell S, Lee AT, Karlson EW, Wolfe F, Kastner DL, Alfredsson L, Altshuler D, et al: Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum Genet. 2005, 77: 1044-1060. 10.1086/498651.PubMedCentralCrossRefPubMed
9.
go back to reference Johansson M, Arlestig L, Hallmans G, Rantapaa-Dahlqvist S: PTPN22 polymorphism and anti-cyclic citrullinated peptide antibodies in combination strongly predicts future onset of rheumatoid arthritis and has a specificity of 100% for the disease. Arthritis Res Ther. 2006, 8: R19-10.1186/ar1868.PubMedCentralCrossRefPubMed Johansson M, Arlestig L, Hallmans G, Rantapaa-Dahlqvist S: PTPN22 polymorphism and anti-cyclic citrullinated peptide antibodies in combination strongly predicts future onset of rheumatoid arthritis and has a specificity of 100% for the disease. Arthritis Res Ther. 2006, 8: R19-10.1186/ar1868.PubMedCentralCrossRefPubMed
10.
go back to reference Barton A, Ollier W: Genetic approaches to the investigation of rheumatoid arthritis. Curr Opin Rheumatol. 2002, 14: 260-269. 10.1097/00002281-200205000-00012.CrossRefPubMed Barton A, Ollier W: Genetic approaches to the investigation of rheumatoid arthritis. Curr Opin Rheumatol. 2002, 14: 260-269. 10.1097/00002281-200205000-00012.CrossRefPubMed
11.
go back to reference Barton A, Eyre S, Bowes J, Ho P, John S, Worthington J: Investigation of the SLC22A4 gene (associated with rheumatoid arthritis in a Japanese population) in a United Kingdom population of rheumatoid arthritis patients. Arthritis Rheum. 2005, 52: 752-758. 10.1002/art.20877.CrossRefPubMed Barton A, Eyre S, Bowes J, Ho P, John S, Worthington J: Investigation of the SLC22A4 gene (associated with rheumatoid arthritis in a Japanese population) in a United Kingdom population of rheumatoid arthritis patients. Arthritis Rheum. 2005, 52: 752-758. 10.1002/art.20877.CrossRefPubMed
12.
go back to reference Swanberg M, Lidman O, Padyukov L, Eriksson P, Akesson E, Jagodic M, Lobell A, Khademi M, Borjesson O, Lindgren CM, et al: MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction. Nat Genet. 2005, 37: 486-494. 10.1038/ng1544.CrossRefPubMed Swanberg M, Lidman O, Padyukov L, Eriksson P, Akesson E, Jagodic M, Lobell A, Khademi M, Borjesson O, Lindgren CM, et al: MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction. Nat Genet. 2005, 37: 486-494. 10.1038/ng1544.CrossRefPubMed
13.
go back to reference Friese MA, Jones EY, Fugger L: MHC II molecules in inflammatory diseases: interplay of qualities and quantities. Trends Immunol. 2005, 26: 559-561. 10.1016/j.it.2005.08.011.CrossRefPubMed Friese MA, Jones EY, Fugger L: MHC II molecules in inflammatory diseases: interplay of qualities and quantities. Trends Immunol. 2005, 26: 559-561. 10.1016/j.it.2005.08.011.CrossRefPubMed
14.
go back to reference Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31: 315-324.CrossRefPubMed Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31: 315-324.CrossRefPubMed
15.
go back to reference Strohmer B, Pichler M, Iglseder B, Paulweber B: Relationship of QT interval duration with carotid intima media thickness in a clinically healthy population undergoing cardiovascular risk screening. J Intern Med. 2005, 257: 238-246. 10.1111/j.1365-2796.2004.01436.x.CrossRefPubMed Strohmer B, Pichler M, Iglseder B, Paulweber B: Relationship of QT interval duration with carotid intima media thickness in a clinically healthy population undergoing cardiovascular risk screening. J Intern Med. 2005, 257: 238-246. 10.1111/j.1365-2796.2004.01436.x.CrossRefPubMed
16.
go back to reference Iglseder B, Mackevics V, Stadlmayer A, Tasch G, Ladurner G, Paulweber B: Plasma adiponectin levels and sonographic phenotypes of subclinical carotid artery atherosclerosis: data from the SAPHIR Study. Stroke. 2005, 36: 2577-2582. 10.1161/01.STR.0000190834.00284.fd.CrossRefPubMed Iglseder B, Mackevics V, Stadlmayer A, Tasch G, Ladurner G, Paulweber B: Plasma adiponectin levels and sonographic phenotypes of subclinical carotid artery atherosclerosis: data from the SAPHIR Study. Stroke. 2005, 36: 2577-2582. 10.1161/01.STR.0000190834.00284.fd.CrossRefPubMed
17.
go back to reference Steinbrocker O, Traeger CH, Batterman RC: Therapeutic criteria in rheumatoid arthritis. JAMA. 1949, 140: 659-662.CrossRef Steinbrocker O, Traeger CH, Batterman RC: Therapeutic criteria in rheumatoid arthritis. JAMA. 1949, 140: 659-662.CrossRef
18.
go back to reference Enattah NS, Sahi T, Savilahti E, Terwilliger JD, Peltonen L, Jarvela I: Identification of a variant associated with adult-type hypolactasia. Nat Genet. 2002, 30: 233-237. 10.1038/ng826.CrossRefPubMed Enattah NS, Sahi T, Savilahti E, Terwilliger JD, Peltonen L, Jarvela I: Identification of a variant associated with adult-type hypolactasia. Nat Genet. 2002, 30: 233-237. 10.1038/ng826.CrossRefPubMed
19.
go back to reference Rosendaal FR, Doggen CJ, Zivelin A, Arruda VR, Aiach M, Siscovick DS, Hillarp A, Watzke HH, Bernardi F, Cumming AM, et al: Geographic distribution of the 20210 G to A prothrombinvariant. Thromb Haemost. 1998, 79: 706-708.PubMed Rosendaal FR, Doggen CJ, Zivelin A, Arruda VR, Aiach M, Siscovick DS, Hillarp A, Watzke HH, Bernardi F, Cumming AM, et al: Geographic distribution of the 20210 G to A prothrombinvariant. Thromb Haemost. 1998, 79: 706-708.PubMed
20.
go back to reference Akkad DA, Jagiello P, Szyld P, Goedde R, Wieczorek S, Gross WL, Epplen JT: Promoter polymorphism rs3087456 in the MHC class II transactivator gene is not associated with susceptibility for selected autoimmune diseases in German patient groups. Int J Immunogenet. 2006, 33: 59-61. 10.1111/j.1744-313X.2006.00568.x.CrossRefPubMed Akkad DA, Jagiello P, Szyld P, Goedde R, Wieczorek S, Gross WL, Epplen JT: Promoter polymorphism rs3087456 in the MHC class II transactivator gene is not associated with susceptibility for selected autoimmune diseases in German patient groups. Int J Immunogenet. 2006, 33: 59-61. 10.1111/j.1744-313X.2006.00568.x.CrossRefPubMed
Metadata
Title
The MHC2TA-168A>G gene polymorphism is not associated with rheumatoid arthritis in Austrian patients
Authors
Babak Yazdani-Biuki
Kerstin Brickmann
Klaus Wohlfahrt
Thomas Mueller
Winfried März
Wilfried Renner
Manuela Gutjahr
Uwe Langsenlehner
Peter Krippl
Thomas C Wascher
Bernhard Paulweber
Winfried Graninger
Hans-Peter Brezinschek
Publication date
01-08-2006
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 4/2006
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar1974

Other articles of this Issue 4/2006

Arthritis Research & Therapy 4/2006 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.